加速超分割放疗联合EP化疗方案治疗局限期小细胞肺癌的临床效果

Abstract
Figure/Table
References (16)
Related Citation (0)

Download: PDF (0 KB) HTML (34 KB)
Export: BibTeX | EndNote (RIS)

Abstract ObjectiveTo investigate the clinical effect of hypedractionated accelerated radiotherapy(HART)combined with EP chemotherapy regimen in treatment of limited-stage small cell lung cancer(LS-SCLC).Methods50 patients of LS-SCLC treated in our hospital from January to December 2014 were selected as subjects,and they were divided into observation group and control group by random number table method,with 25 cases in each group.Control group was given three dimensional conformal radiation therapy and standard EP chemotherapy regimen,while observation group was given intensity modulated radiation therapy and standard EP chemotherapy regimen.After treatment for two months,the total treatment effective rate,progression-free survival,overall survival,two-year survival rate and safety were compared between the two groups.ResultsThe total treatment effective rate of observation group was higher than that of control group,and the difference was statistically significant(P＜0.05).The progression-free survival,overall survival in observation group were longer than those in control group,and the differences were statistically significant(P＜0.05).The two-year survival rate of observation group was 80.00%,which was higher than 52.00%of control group,and the difference was statistically significant(P＜0.05).The incidence of adverse reactions were compared between the two groups,and the difference was not statistically significan(P＞0.05).ConclusionHART combined with EP chemotherapy regimen in treatment of LS-SCLC can increase short-term efficacy,prolong survival time of patients and not add toxic-side effects,which is a safe and efficient treatment regimen.

Key words： Hyperfractionated intensity modulated radiation therapy Limited-stage small cell lung cancer EP regimen

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	JIANG Bi-feng
	LIN Hua-ming

Cite this article:

JIANG Bi-feng,LIN Hua-ming. Clinical effect of hypedractionated accelerated radiotherapy combined with EP chemotherapy regimen in treatment of limited-stage small cell lung cancer[J]. 中国当代医药, 2017, 24(35): 47-49.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2017/V24/I35/47

[1]	封婷，李洪敏，袁芃，等.谷胱甘肽合成酶基因遗传变异与小细胞肺癌患者铂类药物化疗疗效及预后的关系[J].中华肿瘤杂志，2017，39（2）:115-120.
[2]	潘辉，胡艺缤，郭志华，等.经倾向指数匹配后手术切除合并辅助化疗和非手术治疗局限期小细胞肺癌的疗效比较[J].肿瘤预防与治疗，2017，30（2）:85-91.
[3]	陈连刚，侯春立，王梓华，等.同步放化疗治疗老年局限期小细胞肺癌效果观察[J].临床误诊误治，2017，30（2）:90-94.[4]罗云秀，何安兵，龙志雄，等.超分割调强同步放化疗及辅助化疗治疗老年局部晚期食管癌的临床观察[J].肿瘤防治研究，2015，42（8）:814-817.
[5]	陈云萍，李建成，张江灵，等.中晚期非小细胞肺癌调强放疗临床疗效[J].临床荟萃，2015，30（01）:48-51.
[6]	Eisenhauer EA，Therasse P，Bogaerts J，et al.New response evaluation criteria in solid tumours:revised RECIST guideline[J].Eur J Cancer，2009，45（2）:228-247.
[7]	张士法，李迎新，高国栋，等.小细胞肺癌患者的临床特点及预后分析[J].实用癌症杂志，2017，32（4）:593-597，602.
[8]	陈素梅，贾友超.小细胞肺癌靶向治疗和免疫治疗的研究进展[J].武警医学，2016，27（9）:957-960.
[9]	王伟力，钟文，刘大伟，等.胸部放疗分割与局限期小细胞肺癌失败模式的相关性研究[J].现代肿瘤医学，2017，25（2）:216-219.
[10]	赵路军，王平.小细胞肺癌放射治疗新进展--东西方的探索[J].中华放射肿瘤学杂志，2017，26（1）:107-110.
[11]	王大权，徐利明，赵路军，等.诱导化疗无效的局限期小细胞肺癌可能不宜原方案同期放化疗[J].中国肺癌杂志，2016，19（12）:871-879.
[12]	丁新民，冯华松，伏婷婷，等.局限期小细胞肺癌前两周期EP方案化疗有效性与预后[J].中国老年学杂志，2016，36（8）:1880-1882.
[13]	臧婉娜，苏景伟，祝淑钗，等.局限期小细胞肺癌不同局部治疗方式的比较研究[J].中华放射医学与防护杂志，2017，37（1）:40-44.
[14]	郭安定，李化龙，蔡树华.序贯放化疗对老年局限期小细胞肺癌的临床疗效[J].临床肺科杂志，2017，22（6）:1005-1008.
[15]	朱映霞.局限期与广泛期小细胞肺癌患者血清乳酸脱氢酶水平及其与预后的关系[J].实用医院临床杂志，2017，14（1）:68-70.
[16]	黄壬峰，彭少华，李有强，等.局限期小细胞肺癌放化综合治疗疗效及临床预后因素[J].医学综述，2017，23（1）:171-173，178.